L-PLUS 2: Phase 3 Study of Lusutrombopag in Thrombocytopenia with Chronic Liver Disease Undergoing Elective Invasive Procedures

Phase 3, randomised, double-blind trial in Thrombocytopenia and chronic liver disease (CLD) comparing Lusutrombopag with Placebo (2 arms). Primary endpoint: Proportion of patients without platelet transfusion and rescue therapy for bleeding. Started Mar 2015; status: completed.